Video
Dr. Bosse on the Quality of Life With VEGF Plus Radium-223
Author(s):
Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the quality of life when combining VEGF-targeted therapies and radium-223 dichloride (Xofigo) in metastatic renal cell carcinoma (mRCC).
Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the quality of life when combining VEGF-targeted therapies and radium-223 dichloride (Xofigo) in metastatic renal cell carcinoma (mRCC).
There was a secondary endpoint that looked at quality of life, according to Bosse. There was no decrease in pain or improvement of quality of life. This is probably because the entry criteria allowed a maximum of patients with bone disease. The survival of these patients was very short, states Bosse.
Related Videos
Related Content
